Mefloquine as a prophylaxis for malaria needs to be revisited.
Malaria
Mefloquine
Neuropsychiatric side effects
Journal
International journal for parasitology. Drugs and drug resistance
ISSN: 2211-3207
Titre abrégé: Int J Parasitol Drugs Drug Resist
Pays: Netherlands
ID NLM: 101576715
Informations de publication
Date de publication:
12 2021
12 2021
Historique:
received:
28
04
2021
revised:
17
06
2021
accepted:
21
06
2021
pubmed:
3
8
2021
medline:
7
1
2022
entrez:
2
8
2021
Statut:
ppublish
Résumé
According to WHO, 2019 witnessed 229 million cases of malaria globally, of which Africa accounted for 94% of cases. Early diagnosis and treatment are the basis of malaria management, and the need for good chemoprophylaxis especially for people travelling to endemic areas is vital. There are a number of drug options available for the prophylaxis of malaria, mefloquine being one of the drugs used. Mefloquine has been around from the 1970s, and was developed in the United States keeping in mind the soldiers that were being deployed to areas where chloroquine resistant strains of Plasmodium were discovered. Mefloquine was preferred for its once a week dosage. Within a decade of its introduction, reports of the side effects associated with its long-term use surfaced. Mefloquine is now reported to cause a myriad of neuropsychiatric side effects including anxiety, sleep disturbance, depression, dizziness and frank psychosis, especially in patients with pre-existing psychiatric disorders. Many countries like the United States and the United Kingdom have updated their drug boxes to include the warning of these potential neuropsychiatric effects. This paper reviews the side effects of mefloquine and why there is a need to revisit its use in Indian drug policy.
Identifiants
pubmed: 34339933
pii: S2211-3207(21)00030-0
doi: 10.1016/j.ijpddr.2021.06.003
pmc: PMC8342532
pii:
doi:
Substances chimiques
Antimalarials
0
Chloroquine
886U3H6UFF
Mefloquine
TML814419R
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
23-26Informations de copyright
Copyright © 2021 The Authors. Published by Elsevier Ltd.. All rights reserved.
Références
Mil Med. 2008 Dec;173(12):1194-8
pubmed: 19149338
Antimicrob Agents Chemother. 2010 Feb;54(2):792-8
pubmed: 19995933
Am J Trop Med Hyg. 2017 Jan 11;96(1):159-166
pubmed: 28077744
Trop Med Parasitol. 1993 Sep;44(3):257-65
pubmed: 8256107
J R Soc Med. 2007 Apr;100(4):170-4
pubmed: 17404338
Neurol Ther. 2016 Jun;5(1):69-83
pubmed: 27240849
Psychopharmacology (Berl). 2014 Jul;231(14):2771-83
pubmed: 24488404
Can J Hosp Pharm. 2017 Jul-Aug;70(4):323-324
pubmed: 28894322
Clin Infect Dis. 2001 Oct 1;33(7):1015-21
pubmed: 11528574
Trans R Soc Trop Med Hyg. 1999 Jan-Feb;93(1):73-7
pubmed: 10492796
J Travel Med. 1996 Mar 1;3(1):40-45
pubmed: 9815421
Lancet. 1996 Feb 3;347(8997):326
pubmed: 8569381
BMJ Glob Health. 2021 Feb;6(2):
pubmed: 33619041
Med. 2021 May 14;2(5):464-469
pubmed: 35590225
Trop Med Int Health. 1996 Aug;1(4):485-94
pubmed: 8765456
J Parasitol Res. 2015;2015:368064
pubmed: 26576290
Drug Saf. 2004;27(1):25-61
pubmed: 14720085
J Travel Med. 2014 Jan-Feb;21(1):24-32
pubmed: 24383651
PLoS One. 2017 Feb 13;12(2):e0168780
pubmed: 28192434
Travel Med Infect Dis. 2015 Jan-Feb;13(1):80-8
pubmed: 25435322
J Travel Med. 2007 Jul-Aug;14(4):226-32
pubmed: 17617844
BMJ Glob Health. 2021 May;6(5):
pubmed: 33990358
Crit Rev Toxicol. 2021 Mar;51(3):209-216
pubmed: 33905310
Presse Med. 1987 Oct 10;16(33):1654-5
pubmed: 2959933
J Infect Dis. 1996 Jun;173(6):1506-9
pubmed: 8648231
Travel Med Infect Dis. 2009 Jan;7(1):2-6
pubmed: 19174293
Med J Aust. 2005 Feb 21;182(4):168-71
pubmed: 15720172